Cargando…
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
BACKGROUND: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo‐ovarian high‐grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large‐scale, histotype‐speci...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107112/ https://www.ncbi.nlm.nih.gov/pubmed/36572991 http://dx.doi.org/10.1002/cncr.34582 |
_version_ | 1785026534640189440 |
---|---|
author | Kang, Eun‐Young Weir, Ashley Meagher, Nicola S. Farrington, Kyo Nelson, Gregg S. Ghatage, Prafull Lee, Cheng‐Han Riggan, Marjorie J. Bolithon, Adelyn Popovic, Gordana Leung, Betty Tang, Katrina Lambie, Neil Millstein, Joshua Alsop, Jennifer Anglesio, Michael S. Ataseven, Beyhan Barlow, Ellen Beckmann, Matthias W. Berger, Jessica Bisinotto, Christiani Bösmüller, Hans Boros, Jessica Brand, Alison H. Brooks‐Wilson, Angela Brucker, Sara Y. Carney, Michael E. Casablanca, Yovanni Cazorla‐Jiménez, Alicia Cohen, Paul A. Conrads, Thomas P. Cook, Linda S. Coulson, Penny Courtney‐Brooks, Madeleine Cramer, Daniel W. Crowe, Philip Cunningham, Julie M. Cybulski, Cezary Darcy, Kathleen M. El‐Bahrawy, Mona A. Elishaev, Esther Erber, Ramona Farrell, Rhonda Fereday, Sian Fischer, Anna García, María J. Gayther, Simon A. Gentry‐Maharaj, Aleksandra Gilks, C. Blake Grube, Marcel Harnett, Paul R. Harrington, Shariska Petersen Harter, Philipp Hartmann, Arndt Hecht, Jonathan L. Heikaus, Sebastian Hein, Alexander Heitz, Florian Hendley, Joy Hernandez, Brenda Y. Polo, Susanna Hernando Heublein, Sabine Hirasawa, Akira Høgdall, Estrid Høgdall, Claus K. Horlings, Hugo M. Huntsman, David G. Huzarski, Tomasz Jewell, Andrea Jimenez‐Linan, Mercedes Jones, Michael E. Kaufmann, Scott H. Kennedy, Catherine J. Khabele, Dineo Kommoss, Felix K. F. Kruitwagen, Roy F. P. M. Lambrechts, Diether Le, Nhu D. Lener, Marcin Lester, Jenny Leung, Yee Linder, Anna Loverix, Liselore Lubiński, Jan Madan, Rashna Maxwell, G. Larry Modugno, Francesmary Neuhausen, Susan L. Olawaiye, Alexander Olbrecht, Siel Orsulic, Sandra Palacios, José Pearce, Celeste Leigh Pike, Malcolm C. Quinn, Carmel M. Mohan, Ganendra Raj Rodríguez‐Antona, Cristina Ruebner, Matthias Ryan, Andy Salfinger, Stuart G. Sasamoto, Naoko Schildkraut, Joellen M. Schoemaker, Minouk J. Shah, Mitul Sharma, Raghwa Shvetsov, Yurii B. Singh, Naveena Sonke, Gabe S. Steele, Linda Stewart, Colin J. R. Sundfeldt, Karin Swerdlow, Anthony J. Talhouk, Aline Tan, Adeline Taylor, Sarah E. Terry, Kathryn L. Tołoczko, Aleksandra Traficante, Nadia Van de Vijver, Koen K. van der Aa, Maaike A. Van Gorp, Toon Van Nieuwenhuysen, Els van‐Wagensveld, Lilian Vergote, Ignace Vierkant, Robert A. Wang, Chen Wilkens, Lynne R. Winham, Stacey J. Wu, Anna H. Benitez, Javier Berchuck, Andrew Candido dos Reis, Francisco J. DeFazio, Anna Fasching, Peter A. Goode, Ellen L. Goodman, Marc T. Gronwald, Jacek Karlan, Beth Y. Kommoss, Stefan Menon, Usha Sinn, Hans‐Peter Staebler, Annette Brenton, James D. Bowtell, David D. Pharoah, Paul D. P. Ramus, Susan J. Köbel, Martin |
author_facet | Kang, Eun‐Young Weir, Ashley Meagher, Nicola S. Farrington, Kyo Nelson, Gregg S. Ghatage, Prafull Lee, Cheng‐Han Riggan, Marjorie J. Bolithon, Adelyn Popovic, Gordana Leung, Betty Tang, Katrina Lambie, Neil Millstein, Joshua Alsop, Jennifer Anglesio, Michael S. Ataseven, Beyhan Barlow, Ellen Beckmann, Matthias W. Berger, Jessica Bisinotto, Christiani Bösmüller, Hans Boros, Jessica Brand, Alison H. Brooks‐Wilson, Angela Brucker, Sara Y. Carney, Michael E. Casablanca, Yovanni Cazorla‐Jiménez, Alicia Cohen, Paul A. Conrads, Thomas P. Cook, Linda S. Coulson, Penny Courtney‐Brooks, Madeleine Cramer, Daniel W. Crowe, Philip Cunningham, Julie M. Cybulski, Cezary Darcy, Kathleen M. El‐Bahrawy, Mona A. Elishaev, Esther Erber, Ramona Farrell, Rhonda Fereday, Sian Fischer, Anna García, María J. Gayther, Simon A. Gentry‐Maharaj, Aleksandra Gilks, C. Blake Grube, Marcel Harnett, Paul R. Harrington, Shariska Petersen Harter, Philipp Hartmann, Arndt Hecht, Jonathan L. Heikaus, Sebastian Hein, Alexander Heitz, Florian Hendley, Joy Hernandez, Brenda Y. Polo, Susanna Hernando Heublein, Sabine Hirasawa, Akira Høgdall, Estrid Høgdall, Claus K. Horlings, Hugo M. Huntsman, David G. Huzarski, Tomasz Jewell, Andrea Jimenez‐Linan, Mercedes Jones, Michael E. Kaufmann, Scott H. Kennedy, Catherine J. Khabele, Dineo Kommoss, Felix K. F. Kruitwagen, Roy F. P. M. Lambrechts, Diether Le, Nhu D. Lener, Marcin Lester, Jenny Leung, Yee Linder, Anna Loverix, Liselore Lubiński, Jan Madan, Rashna Maxwell, G. Larry Modugno, Francesmary Neuhausen, Susan L. Olawaiye, Alexander Olbrecht, Siel Orsulic, Sandra Palacios, José Pearce, Celeste Leigh Pike, Malcolm C. Quinn, Carmel M. Mohan, Ganendra Raj Rodríguez‐Antona, Cristina Ruebner, Matthias Ryan, Andy Salfinger, Stuart G. Sasamoto, Naoko Schildkraut, Joellen M. Schoemaker, Minouk J. Shah, Mitul Sharma, Raghwa Shvetsov, Yurii B. Singh, Naveena Sonke, Gabe S. Steele, Linda Stewart, Colin J. R. Sundfeldt, Karin Swerdlow, Anthony J. Talhouk, Aline Tan, Adeline Taylor, Sarah E. Terry, Kathryn L. Tołoczko, Aleksandra Traficante, Nadia Van de Vijver, Koen K. van der Aa, Maaike A. Van Gorp, Toon Van Nieuwenhuysen, Els van‐Wagensveld, Lilian Vergote, Ignace Vierkant, Robert A. Wang, Chen Wilkens, Lynne R. Winham, Stacey J. Wu, Anna H. Benitez, Javier Berchuck, Andrew Candido dos Reis, Francisco J. DeFazio, Anna Fasching, Peter A. Goode, Ellen L. Goodman, Marc T. Gronwald, Jacek Karlan, Beth Y. Kommoss, Stefan Menon, Usha Sinn, Hans‐Peter Staebler, Annette Brenton, James D. Bowtell, David D. Pharoah, Paul D. P. Ramus, Susan J. Köbel, Martin |
author_sort | Kang, Eun‐Young |
collection | PubMed |
description | BACKGROUND: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo‐ovarian high‐grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large‐scale, histotype‐specific validation has been performed. The hypothesis was that high‐level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC. METHODS: Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated. RESULTS: High‐level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high‐level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08‐1.47, p = .034, and HR, 1.18; 95% CI, 1.05‐1.32, p = .015, respectively). This was also true for cases with combined high‐level amplification/overexpression (HR, 1.26; 95% CI, 1.09‐1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1‐SD increase; 95% CI, 0.94‐1.06; p = .58). CCNE1 high‐level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss. CONCLUSION: This study provides large‐scale validation that CCNE1 high‐level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC. |
format | Online Article Text |
id | pubmed-10107112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101071122023-04-18 CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study Kang, Eun‐Young Weir, Ashley Meagher, Nicola S. Farrington, Kyo Nelson, Gregg S. Ghatage, Prafull Lee, Cheng‐Han Riggan, Marjorie J. Bolithon, Adelyn Popovic, Gordana Leung, Betty Tang, Katrina Lambie, Neil Millstein, Joshua Alsop, Jennifer Anglesio, Michael S. Ataseven, Beyhan Barlow, Ellen Beckmann, Matthias W. Berger, Jessica Bisinotto, Christiani Bösmüller, Hans Boros, Jessica Brand, Alison H. Brooks‐Wilson, Angela Brucker, Sara Y. Carney, Michael E. Casablanca, Yovanni Cazorla‐Jiménez, Alicia Cohen, Paul A. Conrads, Thomas P. Cook, Linda S. Coulson, Penny Courtney‐Brooks, Madeleine Cramer, Daniel W. Crowe, Philip Cunningham, Julie M. Cybulski, Cezary Darcy, Kathleen M. El‐Bahrawy, Mona A. Elishaev, Esther Erber, Ramona Farrell, Rhonda Fereday, Sian Fischer, Anna García, María J. Gayther, Simon A. Gentry‐Maharaj, Aleksandra Gilks, C. Blake Grube, Marcel Harnett, Paul R. Harrington, Shariska Petersen Harter, Philipp Hartmann, Arndt Hecht, Jonathan L. Heikaus, Sebastian Hein, Alexander Heitz, Florian Hendley, Joy Hernandez, Brenda Y. Polo, Susanna Hernando Heublein, Sabine Hirasawa, Akira Høgdall, Estrid Høgdall, Claus K. Horlings, Hugo M. Huntsman, David G. Huzarski, Tomasz Jewell, Andrea Jimenez‐Linan, Mercedes Jones, Michael E. Kaufmann, Scott H. Kennedy, Catherine J. Khabele, Dineo Kommoss, Felix K. F. Kruitwagen, Roy F. P. M. Lambrechts, Diether Le, Nhu D. Lener, Marcin Lester, Jenny Leung, Yee Linder, Anna Loverix, Liselore Lubiński, Jan Madan, Rashna Maxwell, G. Larry Modugno, Francesmary Neuhausen, Susan L. Olawaiye, Alexander Olbrecht, Siel Orsulic, Sandra Palacios, José Pearce, Celeste Leigh Pike, Malcolm C. Quinn, Carmel M. Mohan, Ganendra Raj Rodríguez‐Antona, Cristina Ruebner, Matthias Ryan, Andy Salfinger, Stuart G. Sasamoto, Naoko Schildkraut, Joellen M. Schoemaker, Minouk J. Shah, Mitul Sharma, Raghwa Shvetsov, Yurii B. Singh, Naveena Sonke, Gabe S. Steele, Linda Stewart, Colin J. R. Sundfeldt, Karin Swerdlow, Anthony J. Talhouk, Aline Tan, Adeline Taylor, Sarah E. Terry, Kathryn L. Tołoczko, Aleksandra Traficante, Nadia Van de Vijver, Koen K. van der Aa, Maaike A. Van Gorp, Toon Van Nieuwenhuysen, Els van‐Wagensveld, Lilian Vergote, Ignace Vierkant, Robert A. Wang, Chen Wilkens, Lynne R. Winham, Stacey J. Wu, Anna H. Benitez, Javier Berchuck, Andrew Candido dos Reis, Francisco J. DeFazio, Anna Fasching, Peter A. Goode, Ellen L. Goodman, Marc T. Gronwald, Jacek Karlan, Beth Y. Kommoss, Stefan Menon, Usha Sinn, Hans‐Peter Staebler, Annette Brenton, James D. Bowtell, David D. Pharoah, Paul D. P. Ramus, Susan J. Köbel, Martin Cancer ORIGINAL ARTICLES BACKGROUND: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo‐ovarian high‐grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large‐scale, histotype‐specific validation has been performed. The hypothesis was that high‐level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC. METHODS: Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated. RESULTS: High‐level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high‐level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08‐1.47, p = .034, and HR, 1.18; 95% CI, 1.05‐1.32, p = .015, respectively). This was also true for cases with combined high‐level amplification/overexpression (HR, 1.26; 95% CI, 1.09‐1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1‐SD increase; 95% CI, 0.94‐1.06; p = .58). CCNE1 high‐level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss. CONCLUSION: This study provides large‐scale validation that CCNE1 high‐level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC. John Wiley and Sons Inc. 2022-12-26 2023-03-01 /pmc/articles/PMC10107112/ /pubmed/36572991 http://dx.doi.org/10.1002/cncr.34582 Text en © 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | ORIGINAL ARTICLES Kang, Eun‐Young Weir, Ashley Meagher, Nicola S. Farrington, Kyo Nelson, Gregg S. Ghatage, Prafull Lee, Cheng‐Han Riggan, Marjorie J. Bolithon, Adelyn Popovic, Gordana Leung, Betty Tang, Katrina Lambie, Neil Millstein, Joshua Alsop, Jennifer Anglesio, Michael S. Ataseven, Beyhan Barlow, Ellen Beckmann, Matthias W. Berger, Jessica Bisinotto, Christiani Bösmüller, Hans Boros, Jessica Brand, Alison H. Brooks‐Wilson, Angela Brucker, Sara Y. Carney, Michael E. Casablanca, Yovanni Cazorla‐Jiménez, Alicia Cohen, Paul A. Conrads, Thomas P. Cook, Linda S. Coulson, Penny Courtney‐Brooks, Madeleine Cramer, Daniel W. Crowe, Philip Cunningham, Julie M. Cybulski, Cezary Darcy, Kathleen M. El‐Bahrawy, Mona A. Elishaev, Esther Erber, Ramona Farrell, Rhonda Fereday, Sian Fischer, Anna García, María J. Gayther, Simon A. Gentry‐Maharaj, Aleksandra Gilks, C. Blake Grube, Marcel Harnett, Paul R. Harrington, Shariska Petersen Harter, Philipp Hartmann, Arndt Hecht, Jonathan L. Heikaus, Sebastian Hein, Alexander Heitz, Florian Hendley, Joy Hernandez, Brenda Y. Polo, Susanna Hernando Heublein, Sabine Hirasawa, Akira Høgdall, Estrid Høgdall, Claus K. Horlings, Hugo M. Huntsman, David G. Huzarski, Tomasz Jewell, Andrea Jimenez‐Linan, Mercedes Jones, Michael E. Kaufmann, Scott H. Kennedy, Catherine J. Khabele, Dineo Kommoss, Felix K. F. Kruitwagen, Roy F. P. M. Lambrechts, Diether Le, Nhu D. Lener, Marcin Lester, Jenny Leung, Yee Linder, Anna Loverix, Liselore Lubiński, Jan Madan, Rashna Maxwell, G. Larry Modugno, Francesmary Neuhausen, Susan L. Olawaiye, Alexander Olbrecht, Siel Orsulic, Sandra Palacios, José Pearce, Celeste Leigh Pike, Malcolm C. Quinn, Carmel M. Mohan, Ganendra Raj Rodríguez‐Antona, Cristina Ruebner, Matthias Ryan, Andy Salfinger, Stuart G. Sasamoto, Naoko Schildkraut, Joellen M. Schoemaker, Minouk J. Shah, Mitul Sharma, Raghwa Shvetsov, Yurii B. Singh, Naveena Sonke, Gabe S. Steele, Linda Stewart, Colin J. R. Sundfeldt, Karin Swerdlow, Anthony J. Talhouk, Aline Tan, Adeline Taylor, Sarah E. Terry, Kathryn L. Tołoczko, Aleksandra Traficante, Nadia Van de Vijver, Koen K. van der Aa, Maaike A. Van Gorp, Toon Van Nieuwenhuysen, Els van‐Wagensveld, Lilian Vergote, Ignace Vierkant, Robert A. Wang, Chen Wilkens, Lynne R. Winham, Stacey J. Wu, Anna H. Benitez, Javier Berchuck, Andrew Candido dos Reis, Francisco J. DeFazio, Anna Fasching, Peter A. Goode, Ellen L. Goodman, Marc T. Gronwald, Jacek Karlan, Beth Y. Kommoss, Stefan Menon, Usha Sinn, Hans‐Peter Staebler, Annette Brenton, James D. Bowtell, David D. Pharoah, Paul D. P. Ramus, Susan J. Köbel, Martin CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study |
title | CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study |
title_full | CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study |
title_fullStr | CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study |
title_full_unstemmed | CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study |
title_short | CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study |
title_sort | ccne1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: an ovarian tumor tissue analysis consortium study |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107112/ https://www.ncbi.nlm.nih.gov/pubmed/36572991 http://dx.doi.org/10.1002/cncr.34582 |
work_keys_str_mv | AT kangeunyoung ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT weirashley ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT meaghernicolas ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT farringtonkyo ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT nelsongreggs ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT ghatageprafull ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT leechenghan ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT rigganmarjoriej ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT bolithonadelyn ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT popovicgordana ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT leungbetty ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT tangkatrina ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT lambieneil ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT millsteinjoshua ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT alsopjennifer ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT anglesiomichaels ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT atasevenbeyhan ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT barlowellen ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT beckmannmatthiasw ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT bergerjessica ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT bisinottochristiani ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT bosmullerhans ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT borosjessica ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT brandalisonh ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT brookswilsonangela ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT bruckersaray ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT carneymichaele ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT casablancayovanni ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT cazorlajimenezalicia ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT cohenpaula ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT conradsthomasp ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT cooklindas ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT coulsonpenny ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT courtneybrooksmadeleine ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT cramerdanielw ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT crowephilip ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT cunninghamjuliem ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT cybulskicezary ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT darcykathleenm ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT elbahrawymonaa ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT elishaevesther ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT erberramona ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT farrellrhonda ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT feredaysian ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT fischeranna ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT garciamariaj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT gaythersimona ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT gentrymaharajaleksandra ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT gilkscblake ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT grubemarcel ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT harnettpaulr ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT harringtonshariskapetersen ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT harterphilipp ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT hartmannarndt ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT hechtjonathanl ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT heikaussebastian ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT heinalexander ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT heitzflorian ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT hendleyjoy ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT hernandezbrenday ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT polosusannahernando ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT heubleinsabine ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT hirasawaakira ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT høgdallestrid ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT høgdallclausk ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT horlingshugom ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT huntsmandavidg ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT huzarskitomasz ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT jewellandrea ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT jimenezlinanmercedes ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT jonesmichaele ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT kaufmannscotth ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT kennedycatherinej ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT khabeledineo ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT kommossfelixkf ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT kruitwagenroyfpm ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT lambrechtsdiether ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT lenhud ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT lenermarcin ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT lesterjenny ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT leungyee ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT linderanna ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT loverixliselore ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT lubinskijan ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT madanrashna ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT maxwellglarry ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT modugnofrancesmary ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT neuhausensusanl ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT olawaiyealexander ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT olbrechtsiel ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT orsulicsandra ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT palaciosjose ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT pearcecelesteleigh ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT pikemalcolmc ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT quinncarmelm ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT mohanganendraraj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT rodriguezantonacristina ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT ruebnermatthias ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT ryanandy ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT salfingerstuartg ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT sasamotonaoko ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT schildkrautjoellenm ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT schoemakerminoukj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT shahmitul ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT sharmaraghwa ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT shvetsovyuriib ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT singhnaveena ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT sonkegabes ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT steelelinda ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT stewartcolinjr ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT sundfeldtkarin ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT swerdlowanthonyj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT talhoukaline ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT tanadeline ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT taylorsarahe ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT terrykathrynl ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT tołoczkoaleksandra ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT traficantenadia ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT vandevijverkoenk ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT vanderaamaaikea ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT vangorptoon ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT vannieuwenhuysenels ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT vanwagensveldlilian ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT vergoteignace ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT vierkantroberta ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT wangchen ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT wilkenslynner ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT winhamstaceyj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT wuannah ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT benitezjavier ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT berchuckandrew ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT candidodosreisfranciscoj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT defazioanna ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT faschingpetera ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT goodeellenl ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT goodmanmarct ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT gronwaldjacek ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT karlanbethy ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT kommossstefan ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT menonusha ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT sinnhanspeter ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT staeblerannette ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT brentonjamesd ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT bowtelldavidd ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT pharoahpauldp ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT ramussusanj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy AT kobelmartin ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy |